The company is privately held and is being supported by its 8 investors, both private and government. Although mostly Finance investors, they share the excitement inherent to Life Sciences research.
In detail, SIRION Biotech believes in the future of viral vectors in various applications:
- Gene Function Research,
- Target Validation,
- Gene Therapy and
"The viral vectors are what will differentiate the various gene therapy approaches", writes Joshua Schimmer of Piper Jaffray in his study by Lazard Capital Markets titled "Gene Therapy: The Time is Now".
The company welcomes new investors, be it Finance or Strategic investors, to help it grow even more strongly with the many opportunities along the way and to help it benefit from technology development in this exciting industry, Please contact Management for further information about the company and its future plans.